Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 9,549 matching trials from the live ClinicalTrials.gov search.

Filters: Birmingham, Alabama Clear all

Conditions: Parkinson Disease
Interventions: Implantable pulse generator (deep brain stimulator); Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 20 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin; Drug · Other · Procedure + 1 more
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 3,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 480
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more

Conditions: Anemia
Interventions: methoxy polyethylene glycol-epoetin beta, Epoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Rainbow City, Alabama • Hot Springs, Arizona + 41 more

Conditions: Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Interventions: Eribulin mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 36 more

Conditions: Hypertension
Interventions: Placebo, IONIS-AGT-LRx; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 48
States / cities: Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 44 more

Conditions: Sickle Cell Disease
Interventions: VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Mitral Valve Regurgitation, Mitral Regurgitation
Interventions: MitraClip G4 System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 20 more

Conditions: Epilepsy
Interventions: Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand", lamotrigine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Des Moines, Iowa • Iowa City, Iowa + 5 more

Conditions: Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions: brentuximab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Duarte, California • Stanford, California + 12 more

Conditions: Cystic Fibrosis
Interventions: Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Preterm Infants
Interventions: Experimental human milk fortifier, Control human milk fortifier; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: Up to 21 Days
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Tampa, Florida + 11 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler; Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 1,087 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 83
States / cities: Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more

Conditions: Kidney Transplant
Interventions: Abatacept, Standard of Care at US Transplant Centers; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Verapamil, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Asthma
Interventions: Fluticasone propionate, Fluticasone furoate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 55
States / cities: Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 45 more

Conditions: HIV Infections
Interventions: Efavirenz, Emtricitabine, Stavudine, Didanosine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 51
States / cities: Birmingham, Alabama • Berkeley, California • Concord, California + 38 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin degludec, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 146
States / cities: Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more

Conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 149
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more

Conditions: Bariatric Surgery, Osteoporosis, Fractures, Bone, Roux En-Y Gastric Bypass, Sleeve Gastrectomy, Menopause, Premenopause
Interventions: Roux en Y Gastric Bypass Pre-menopausal, Roux en Y Gastric Bypass Post-menopausal, Sleeve Gastrectomy Pre-menopausal, Sleeve Gastrectomy Post-menopausal; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cardiac Arrhythmia
Interventions: cardiac mapping and radiofrequency ablation procedure; Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 4 more

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more

Conditions: Non-melanoma Skin Cancer
Interventions: UAB30, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Tuberous Sclerosis Complex, Seizures
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Psoriasis
Interventions: Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more

Search by objective public record fields.

Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

MitraClip EXPAND G4 Study

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

Evaluation of a Novel Human Milk Fortifier in Preterm Infants

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Skeletal Health in Bariatric Surgery Patients

EnSite Precision Observational Study

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment